Equities Analysts Issue Forecasts for LEXX Q2 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Research analysts at Zacks Research issued their Q2 2026 earnings per share estimates for shares of Lexaria Bioscience in a research report issued on Tuesday, February 10th. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings per share of ($0.07) for the quarter. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share. Zacks Research also issued estimates for Lexaria Bioscience’s Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.26) EPS and FY2027 earnings at ($0.31) EPS.

A number of other research firms also recently commented on LEXX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lexaria Bioscience in a report on Monday, December 29th. Wall Street Zen cut Lexaria Bioscience from a “hold” rating to a “sell” rating in a report on Sunday, December 7th. Finally, HC Wainwright reduced their price objective on Lexaria Bioscience from $4.00 to $1.50 and set a “buy” rating on the stock in a research report on Friday, December 26th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.50.

Lexaria Bioscience Trading Down 6.5%

NASDAQ:LEXX opened at $0.64 on Thursday. The company has a market cap of $15.87 million, a P/E ratio of -1.14 and a beta of 0.56. Lexaria Bioscience has a twelve month low of $0.46 and a twelve month high of $1.90. The company’s 50-day moving average price is $0.77 and its 200-day moving average price is $0.92.

Lexaria Bioscience (NASDAQ:LEXX) last announced its earnings results on Tuesday, January 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.14 million. Lexaria Bioscience had a negative net margin of 1,685.84% and a negative return on equity of 226.58%.

Institutional Trading of Lexaria Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Lexaria Bioscience during the 3rd quarter valued at approximately $28,000. Byrne Asset Management LLC grew its position in Lexaria Bioscience by 236.8% in the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock worth $65,000 after acquiring an additional 74,180 shares during the period. Finally, Geode Capital Management LLC grew its position in Lexaria Bioscience by 25.7% in the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after acquiring an additional 44,939 shares during the period. Institutional investors and hedge funds own 13.06% of the company’s stock.

About Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.